172 related articles for article (PubMed ID: 17845504)
1. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies.
Krishnan S; Montcrief S
Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):231-40. PubMed ID: 17845504
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
3. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
Jasinski DR; Krishnan S
J Psychopharmacol; 2009 Jun; 23(4):419-27. PubMed ID: 19329547
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug.
Hutson PH; Pennick M; Secker R
Neuropharmacology; 2014 Dec; 87():41-50. PubMed ID: 24594478
[TBL] [Abstract][Full Text] [Related]
6. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
9. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
Krishnan SM; Stark JG
Curr Med Res Opin; 2008 Jan; 24(1):33-40. PubMed ID: 18021493
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.
Ermer JC; Haffey MB; Doll WJ; Martin P; Sandefer EP; Dennis K; Corcoran M; Trespidi L; Page RC
Drug Metab Dispos; 2012 Feb; 40(2):290-7. PubMed ID: 22039171
[TBL] [Abstract][Full Text] [Related]
11. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.
Jasinski DR; Krishnan S
J Psychopharmacol; 2009 Jun; 23(4):410-8. PubMed ID: 18635707
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler LA; Alperin S; Leon T; Faraone SV
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
[TBL] [Abstract][Full Text] [Related]
13. Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania.
Macêdo DS; de Lucena DF; Queiroz AI; Cordeiro RC; Araújo MM; Sousa FC; Vasconcelos SM; Hyphantis TN; Quevedo J; McIntyre RS; Carvalho AF
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():230-7. PubMed ID: 23333378
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
15. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.
Ermer JC; Pennick M; Frick G
Clin Drug Investig; 2016 May; 36(5):341-56. PubMed ID: 27021968
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
20. NTP technical report on the toxicity studies of methacrylonitrile (CAS No. 126-98-7). Administered by gavage to F344/N rats and B6C3F1 mice.
Ghanayem BI
Toxic Rep Ser; 2000 May; (47):1-56, A1-E6. PubMed ID: 11803706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
